A novel embryonic plasticity gene signature that predicts metastatic competence and clinical outcome

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Soundararajan, Rama ^a   Paranjape, Anurag N ^a   Barsan, Valentin ^a   Chang, Jeffrey T ^d   Mani, Sendurai A ^a,b,c  

^a Department of Translational Molecular Pathology ^*  (United States)

^b Metastasis Research Center   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTOME;

ANIMAL; BREAST TUMOR; DISEASE FREE SURVIVAL; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KAPLAN MEIER METHOD; METABOLISM; METASTASIS; MORTALITY; MOUSE; MOUSE EMBRYONIC STEM CELL; PATHOLOGY; PHYSIOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MICE; MOUSE EMBRYONIC STEM CELLS; NEOPLASM METASTASIS; TRANSCRIPTOME; TREATMENT OUTCOME;

EID: 84934764818     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep11766     Document Type: Article

References (60)

1. Kalluri, R. & Weinberg, R. A. The basics of epithelial-mesenchymal transition. Journal of Clinical Investigation 119, 1420-1428 (2009).
2. Mani, S. A. et al. The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells. Cell 133, 704-715 (2008).
3. Eastham, A. M. et al. Epithelial-mesenchymal transition events during human embryonic stem cell differentiation. Cancer Research 67, 11254-11262 (2007).
4. Zheng, H. & Kang, Y. Multilayer control of the EMT master regulators. Oncogene 33, 1755-1763 (2014).
5. Craene, B. D. & Berx, G. Regulatory networks defining EMT during cancer initiation and progression. Nature Reviews Cancer 13, 97-110 (2013).
6. Thiery, J. P. & Sleeman, J. P. Complex networks orchestrate epithelial-mesenchymal transitions. Nature reviews Molecular cell biology 7, 131-142 (2006).
7. Moody, S. E. et al. The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 8, 197-209 (2005).
8. Taube, J. H. et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudinlow and metaplastic breast cancer subtypes. Proceedings of the National Academy of Sciences of the United States of America 107, 15449-15454 (2010).
9. Ocaña, O. et al. Metastatic Colonization Requires the Repression of the Epithelial-Mesenchymal Transition Inducer Prrx1. Cancer Cell 22, 709-724 (2012).
10. Tsai, J. H., Donaher, J. L., Murphy, D. A., Chau, S. & Yang, J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 22, 725-736 (2012).
11. Thiery, J. P., Acloque, H., Huang, R. Y. J. & Nieto, M. A. Epithelial-Mesenchymal Transitions in Development and Disease. Cell 139, 871-890 (2009).
12. Thiery, J. P. & Lim, C. T. Tumor dissemination: An EMT affair. Cancer Cell 23, 272-273 (2013).
13. Al-Dhfyan, A. Embryonic signature in breast cancers; Pluripotency roots of cancer stem cells. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society 21, 229-232 (2013).
14. Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. The New England journal of medicine 351, 2817-2826 (2004).
15. Palmer, N. P., Schmid, P. R., Berger, B. & Kohane I. S. A gene expression profile of stem cell pluripotentiality and differentiation is conserved across diverse solid and hematopoietic cancers. Genome biology 13, R71 (2012).
16. Hassan, K. A., Chen, G., Kalemkerian, G. P., Wicha, M. S. & Beer, D. G. An embryonic stem cell-like signature identifies poorly differentiated lung adenocarcinoma but not squamous cell carcinoma. Clin Cancer Res 15, 6386-6390 (2009).
17. Yin, Z. Q. et al. A 41-gene signature derived from breast cancer stem cells as a predictor of survival. Journal of experimental & clinical cancer research : CR 33, 49 (2014).
18. Tan, T. Z. et al. Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. EMBO Mol Med 6, 1279-1293 (2014).
19. Karlsson, J. et al. Clear cell sarcoma of the kidney demonstrates an embryonic signature indicative of a primitive nephrogenic origin. Genes, chromosomes & cancer 53, 381-391 (2014).
20. Zvelebil, M. et al. Embryonic mammary signature subsets are activated in Brca1-/-and basal-like breast cancers. Breast Cancer Res 15, R25 (2013).
21. Kim, J. & Orkin, S. H. Embryonic stem cell-specific signatures in cancer: insights into genomic regulatory networks and implications for medicine. Genome medicine 3, 75 (2011).
22. Patsialou, A. et al. Selective gene-expression profiling of migratory tumor cells in vivo predicts clinical outcome in breast cancer patients. Breast Cancer Res 14, R139 (2012).
23. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
24. Prat, A. et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12, R68 (2010).
25. Prat, A. & Perou, C. M. Deconstructing the molecular portraits of breast cancer. Mol Oncol 5, 5-23 (2011).
26. Baird, R. D. & Caldas, C. Genetic heterogeneity in breast cancer: the road to personalized medicine? BMC Med 11, 151 (2013).
27. Hay, E. D. Role of cell-matrix contacts in cell migration and epithelial-mesenchymal transformation. Cell differentiation and development : the official journal of the International Society of Developmental Biologists 32, 367-375 (1990).
28. Wu, C. et al. BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome biology 10, R130 (2009).
29. Yilmaz, M. & Christofori, G. Mechanisms of motility in metastasizing cells. Molecular cancer research : MCR 8, 629-642 (2010).
30. Trimboli, A. J. et al. Direct evidence for epithelial-mesenchymal transitions in breast cancer. Cancer Res 68, 937-945 (2008).
31. Brabletz, T. et al. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A 98, 10356-10361 (2001).
32. Chikaishi, Y., Uramoto, H. & Tanaka, F. The EMT status in the primary tumor does not predict postoperative recurrence or disease-free survival in lung adenocarcinoma. Anticancer Res 31, 4451-4456 (2011).
33. Celià-Terrassa, T. et al. Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. Journal of Clinical Investigation 122, 1849-1868 (2012).
34. Gunasinghe NPAD, Wells A., Thompson, E. W. & Hugo, H. J. Mesenchymal-epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer. Cancer and Metastasis Reviews 31, 469-478 (2012).
35. Chaffer, C. L. et al. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res 66, 11271-11278 (2006).
36. Brabletz, T. To differentiate or not-routes towards metastasis. Nature Reviews Cancer 12, 425-436 (2012).
37. Brabletz, T. EMT and MET in Metastasis: Where Are the Cancer Stem Cells? Cancer Cell 22, 699-701 (2012).
38. Liu, S. et al. Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem cell reports 2, 78-91 (2014).
39. Rousseaux, S. et al. Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med 5, 186ra166 (2013).
40. Singhai, R. et al. E-Cadherin as a diagnostic biomarker in breast cancer. North American journal of medical sciences 3, 227-233 (2011).
41. Gamallo, C. et al. Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. The American journal of pathology 142, 987-993 (1993).
42. Moll, R., Mitze, M., Frixen, U. H. & Birchmeier, W. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. The American journal of pathology 143, 1731-1742 (1993).
43. Siitonen, S. M. et al. Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. Am J Clin Pathol 105, 394-402 (1996).
44. Swiatoniowski, G. et al. E-cadherin and fibronectin expressions have no prognostic role in stage II ductal breast cancer. Anticancer Res 25, 2879-2883 (2005).
45. van 't Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
46. Glas, A. M. et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 7, 278 (2006).
47. Mittempergher, L. et al. A gene signature for late distant metastasis in breast cancer identifies a potential mechanism of late recurrences. Mol Oncol 7, 987-999 (2013).
48. Liu, R. et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. The New England journal of medicine 356, 217-226 (2007).
49. Leth-Larsen, R. et al. Functional heterogeneity within the CD44 high human breast cancer stem cell-like compartment reveals a gene signature predictive of distant metastasis. Mol Med 18, 1109-1121 (2012).
50. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 42, D7-17 (2014).
51. Smyth, G. K. limma: Linear Models for Microarray Data. In: Bioinformatics and Computational Biology Solutions Using R and Bioconductor (eds Gentleman, R., Carey, V. J., Huber, W., Irizarry, R. A., Dudoit, S). Springer (2005).
52. Kao, K. J., Chang, K. M., Hsu, H. C. & Huang, A. T. Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization. BMC Cancer 11, 143 (2011).
53. Loi, S. et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 25, 1239-1246 (2007).
54. Desmedt, C. et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13, 3207-3214 (2007).
55. Schmidt, M. et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 68, 5405-5413 (2008).
56. Pawitan, Y. et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 7, R953-964 (2005).
57. Bos, P. D. et al. Genes that mediate breast cancer metastasis to the brain. Nature 459, 1005-1009 (2009).
58. Ivshina, A. V. et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 66, 10292-10301 (2006).
59. Sabatier, R. et al. A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Res Treat 126, 407-420 (2011).
60. Irizarry, R. A. et al. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31, e15 (2003).